Mercury Data Sciences, a Houston-based science firm, has recently released an AI-driven app designed to help researchers unfurl COVID-19-related information present in the biomedical literature. The app simplifies the access to patient data and sheds light on subjects like genes, proteins, drugs, and diseases. The firm is applying Artificial Intelligence (AI) technology to agricultural biotech, cancer therapeutics, and neuroscience.
The platform can ferret out information about genetics. This allows the companies seeking gene-editing targets to make new crops, provide more nutritious food, and increase their sustainability. It also will enable the plants to withstand climatic changes to de-risk their genomic analysis by quickly accessing its protein portion and genes of that particular plant.
The firm has stated that its platform provides broader and long-lasting benefits. The platform relies on an AI concept known as natural language processing (NLP) to mine scientific literature. It delivers real-time results to researchers. The NLP platform will be publicly available as an app; this will enable scientists to discover biological relationships that contain COVID research efficiently. This app will allow researchers to sift through literature and dig up data bout new genes.